logo
Laurus Labs Ltd.
06 Jul 2021
849.35
-2.86%
Motilal Oswal
Laurus Labs (LAURUS)'s Annual Report Analysis indicates a sharp improvement in ROE, led by a strong head-start in Finished dosage forms (FDF), improving operating profit, and a reduced interest rate. Since its journey from ARV API to a fully integrated pharmaceutical company over FY0621, LAURUS is on the path to strengthening its capabilities/capacity in Contract...
Laurus Labs Ltd. is trading above all available SMAs
More from Laurus Labs Ltd.
Recommended